294 related articles for article (PubMed ID: 10549683)
21. Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study.
Randall S; Roehrs TA; Roth T
Sleep; 2012 Nov; 35(11):1551-7. PubMed ID: 23115404
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trial.
Maroo N; Hazra A; Das T
Indian J Pharmacol; 2013; 45(1):34-9. PubMed ID: 23543804
[TBL] [Abstract][Full Text] [Related]
23. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
[TBL] [Abstract][Full Text] [Related]
24. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
[TBL] [Abstract][Full Text] [Related]
25. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem.
Kryger MH; Steljes D; Pouliot Z; Neufeld H; Odynski T
Sleep; 1991 Oct; 14(5):399-407. PubMed ID: 1759092
[TBL] [Abstract][Full Text] [Related]
26. Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study.
Roehrs TA; Randall S; Harris E; Maan R; Roth T
Sleep; 2011 Feb; 34(2):207-12. PubMed ID: 21286241
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
28. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening.
Zammit GK; Corser B; Doghramji K; Fry JM; James S; Krystal A; Mangano RM
J Clin Sleep Med; 2006 Oct; 2(4):417-23. PubMed ID: 17557470
[TBL] [Abstract][Full Text] [Related]
29. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo.
Roth T; Roehrs T; Vogel G
Sleep; 1995 May; 18(4):246-51. PubMed ID: 7618022
[TBL] [Abstract][Full Text] [Related]
30. Nonorganic insomnia in generalized anxiety disorder. 2. Comparative studies on sleep, awakening, daytime vigilance and anxiety under lorazepam plus diphenhydramine (Somnium) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping methods.
Saletu B; Saletu-Zyhlarz G; Anderer P; Brandstätter N; Frey R; Gruber G; Klösch G; Mandl M; Grünberger J; Linzmayer L
Neuropsychobiology; 1997; 36(3):130-52. PubMed ID: 9313245
[TBL] [Abstract][Full Text] [Related]
31. Zolpidem increases GABA in depressed volunteers maintained on SSRIs.
Licata SC; Jensen JE; Conn NA; Winer JP; Lukas SE
Psychiatry Res; 2014 Oct; 224(1):28-33. PubMed ID: 25082715
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients.
Walsh JK; Soubrane C; Roth T
Am J Geriatr Psychiatry; 2008 Jan; 16(1):44-57. PubMed ID: 18165461
[TBL] [Abstract][Full Text] [Related]
33. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.
Roehrs TA; Randall S; Harris E; Maan R; Roth T
J Psychopharmacol; 2012 Aug; 26(8):1088-95. PubMed ID: 22004689
[TBL] [Abstract][Full Text] [Related]
34. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study.
Hajak G; Cluydts R; Declerck A; Estivill SE; Middleton A; Sonka K; Unden M
Int Clin Psychopharmacol; 2002 Jan; 17(1):9-17. PubMed ID: 11800507
[TBL] [Abstract][Full Text] [Related]
35. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.
Roth T; Hull SG; Lankford DA; Rosenberg R; Scharf MB;
Sleep; 2008 Sep; 31(9):1277-84. PubMed ID: 18788653
[TBL] [Abstract][Full Text] [Related]
36. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia.
Erman MK; Zammit G; Rubens R; Schaefer K; Wessel T; Amato D; Caron J; Walsh JK
J Clin Sleep Med; 2008 Jun; 4(3):229-34. PubMed ID: 18595435
[TBL] [Abstract][Full Text] [Related]
37. Effects of zolpidem on cyclic alternating pattern, an objective marker of sleep instability, in Japanese patients with psychophysiological insomnia: a randomized crossover comparative study with placebo.
Ozone M; Yagi T; Itoh H; Tamura Y; Inoue Y; Uchimura N; Sasaki M; Shimizu T; Terzano MG; Parrino L
Pharmacopsychiatry; 2008 May; 41(3):106-14. PubMed ID: 18484552
[TBL] [Abstract][Full Text] [Related]
38. The effects of trazodone on sleep in patients treated with stimulant antidepressants.
Kaynak H; Kaynak D; Gözükirmizi E; Guilleminault C
Sleep Med; 2004 Jan; 5(1):15-20. PubMed ID: 14725822
[TBL] [Abstract][Full Text] [Related]
39. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
40. Zolpidem, a valuable alternative to benzodiazepine hypnotics for chronic insomnia?
Declerck A; Smits M
J Int Med Res; 1999; 27(6):253-63. PubMed ID: 10726234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
